Obicetrapib is under clinical development by NewAmsterdam Pharma Company and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Obicetrapib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Obicetrapib (AMG-899, DEZ-001, TA-8995) is under development for Alzheimer’s disease, atherosclerosis, dyslipidemia and heterozygous familial hypercholesterolemia (HeFH) and diabetes. It is administered orally as once daily formulation. The drug candidate acts by targeting cholesteryl ester transfer protein (CETP).
It was under development for was under development for the treatment of mild dyslipidemia by Amgen.
NewAmsterdam Pharma Company overview
NewAmsterdam Pharma Company (NAP), a clinical stage biotechnology company focused on the research and development of transformative therapies for cardio-renal diseases. The company is headquartered in the Netherlands.
For a complete picture of Obicetrapib’s drug-specific PTSR and LoA scores, buy the report here.